How gut bacteria affect the development and treatment of AIDS-related cancer
Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapy
This study is looking at how the bacteria in your gut might affect the development and treatment of Kaposi's sarcoma in people with AIDS, with the goal of finding new ways to help improve care and outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10925307 on NIH RePORTER |
What this research studies
This research investigates the role of microbiota, or gut bacteria, in the development and treatment outcomes of Kaposi's sarcoma (KS) in patients with AIDS. The study aims to understand how an imbalance in these bacteria can influence the immune response and inflammation, which are critical factors in cancer progression. By examining specific microbiota and their effects on KS, the researchers hope to identify new therapeutic targets and prognostic biomarkers that could improve treatment for affected patients. The research involves collaboration among experts in HIV, cancer biology, and microbiome studies to ensure a comprehensive approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have been diagnosed with Kaposi's sarcoma.
Not a fit: Patients without HIV or those who do not have Kaposi's sarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and outcomes for patients with AIDS-related Kaposi's sarcoma.
How similar studies have performed: Previous research has shown promising results in understanding the role of microbiota in cancer development, suggesting that this approach could yield significant insights.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Gao, Shou-Jiang — University of Pittsburgh at Pittsburgh
- Study coordinator: Gao, Shou-Jiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.